Share this article
Share this article
TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase 3 registrational study. All currently enrolled patients in both arms will be given the opportunity to transition to an active regimen of Aramchol. This is designed to evaluate treatment response kinetics, pharmacokinetics (PK) and safety of twice daily administration (BID) of Aramchol 300mg in approximately 150 subjects at various time points with the results of a second biopsy coming as early as 24 weeks after initiation of treatment. The 150 patients are expected to be comprised of both current ARMOR patients as well as new patients.